Jürgen Sühnel jsuehnel@imb-jena.de Institute of Molecular Biotechnology, Jena Centre for...

Preview:

Citation preview

Jürgen SühnelJürgen Sühneljsuehnel@imb-jena.dejsuehnel@imb-jena.de

Institute of Molecular Biotechnology, Jena Centre for BioinformaticsInstitute of Molecular Biotechnology, Jena Centre for BioinformaticsJena / GermanyJena / Germany

Supplementary Material: http://www.imb-jena.de/www_bioc/3D/

3D Structures of Biological Macromolecules3D Structures of Biological MacromoleculesPart 3Part 3

Drug Research and Design Drug Research and Design

 

Example of Drug Discovery Example of Drug Discovery

 

Example of Drug Discovery Example of Drug Discovery

Pacific yew tree(Eibe)

Example of Drug Discovery Example of Drug Discovery

Development of Drug ResearchDevelopment of Drug Research

www.kubinyi.de

Drug TimelineDrug Timeline

www.kubinyi.de

Drug TimelineDrug Timeline

www.kubinyi.de

 

Drug DiscoveryDrug Discovery

Cost for discovering and developing a new drug:several € 100 million up to € 1000 million (average € 802 M)

Time to market:10 – 15 years

Costs in Drug ResearchCosts in Drug Research

ww.kubinyi.de

Pharma Sales and Eearnings in 1999-2002Pharma Sales and Eearnings in 1999-2002

ww.kubinyi.de

The World´s Top-Selling Drugs in 2004The World´s Top-Selling Drugs in 2004

 

Disciplines Involved in Drug DevelopmentDisciplines Involved in Drug Development

Molecular Conceptor

The Role of Molecular StructureThe Role of Molecular Structure

Molecular Conceptor

The Pharmacophore ConceptThe Pharmacophore Concept

Molecular Conceptor

Mechanisms of Drug Action – Definitions IMechanisms of Drug Action – Definitions I

www.kubinyi.de

Mechanisms of Drug Action – Definitions IIMechanisms of Drug Action – Definitions II

www.kubinyi.de

 

Serendipity - PenicillinSerendipity - Penicillin

Molecular Conceptor

 

Serendipity - AspirinSerendipity - Aspirin

Molecular Conceptor

 

Strategíes in Drug DesignStrategíes in Drug Design

www.kubinyi.de

 

3D Structures In Drug Research3D Structures In Drug Research

www.kubinyi.de

 

Computational Approaches to Drug DiscoveryComputational Approaches to Drug Discovery

Target identification Lead discovery Lead optimization

Ligand-based design Receptor-based design (Docking)

Database screening (Virtual screening) Supporting combinatorial chemistry

Lead Structure IdentificationLead Structure Identification

www.kubinyi.de

Lead Structure SearchLead Structure Search

www.kubinyi.de

 

Lead Structures: Endogeneous NeurotransmittersLead Structures: Endogeneous Neurotransmitters

www.kubinyi.de

Lead OptimizationLead Optimization

www.kubinyi.de

 

What is QSAR ?What is QSAR ?

 

Basic Requirements in QSAR StudiesBasic Requirements in QSAR Studies

 

QSARQSAR

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

 

QSAR Parameters -LipophilicityQSAR Parameters -Lipophilicity

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

QSAR ParametersQSAR Parameters

www.kubinyi.de

 

A QSAR Success StoryA QSAR Success Story

www.kubinyi.de

 

A QSAR Success StoryA QSAR Success Story

www.kubinyi.de

pI50 – concentration of test compound required to reduce the protein content of cell by 50%

 

3D-QSAR - CoMFA3D-QSAR - CoMFA

www.kubinyi.de

 

Molecular Superposition of D Receptor LigandsMolecular Superposition of D Receptor Ligands

www.kubinyi.de

 

The Future: Pharmagenomics and Personalized MedicineThe Future: Pharmagenomics and Personalized Medicine

www.kubinyi.de

 

3D-QSAR - CoMFA3D-QSAR - CoMFA

www.kubinyi.de

 

3D-QSAR - CoMFA3D-QSAR - CoMFA

www.kubinyi.de

 

Electrostatic and Van-der-Waals InteractionsElectrostatic and Van-der-Waals Interactions

 

Drug Discovery – Ligand-based DesignDrug Discovery – Ligand-based Design

ComparativeMolecularField Analysis

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Hydrogen Bonds and Ligand AffinitiesHydrogen Bonds and Ligand Affinities

www.kubinyi.de

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

Molecular Conceptor

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

 

Drug Discovery – Receptor-based Design (Structure-based Design)Drug Discovery – Receptor-based Design (Structure-based Design)

 

Combinatorial Diversity in NatureCombinatorial Diversity in Nature

www.kubinyi.de

Classical vs. Combinational ChemistryClassical vs. Combinational Chemistry

ww.kubinyi.de

Combinatorial LibraryCombinatorial Library

ww.kubinyi.de

Combinatorial LibraryCombinatorial Library

ww.kubinyi.de

Types and Features of Combinatorial LibrariesTypes and Features of Combinatorial Libraries

ww.kubinyi.de

Virtual Screening: Select subsets of compounds for assay that are more likely to contain active hits than a sample chosen at random

Time Scales: Docking of 1 compound 30 s

(SGI R10000 processor) Docking of the 1.1 million data set 6 days

(64-processor SGI ORIGIN)

Virtual ScreeningVirtual Screening

ACD-SC: Database from Molecular Design Ltd.Agonists: Known active compoundsDocking of ligands to the estrogen receptor (nuclear hormone receptor)

Virtual ScreeningVirtual Screening

Lipinski‘s „Rule of Five“Lipinski‘s „Rule of Five“

Compounds are likely to have a good absorption and permeationin biological systems and are thus more likely to be successful drug candidatesif they meet the following criteria:

• 5 or fewer H-bond donors• 10 or fewer H-bond acceptors• Molecular weight less than or equal to 500• Calculated log P less than or equal to 5• „Compound classes that are substrates for biological transporters are exceptions to the rule“.

 

ADMEADME

 

The Future: Pharmagenomics and Personalized MedicineThe Future: Pharmagenomics and Personalized Medicine

www.kubinyi.de

 

Prediction IssuesPrediction Issues

www.kubinyi.de